Search - tctmd.com

Displaying 221 - 238 of 238

Sort: Relevancy | Date

News Industry News

Trial of Medtronic Symplicity™ Renal Denervation System Shows Significant Blood Pressure Reduction, With No Evidence of Renal Impairment, at Six Months Post Treatment

April 27, 2012

Presentation GI2 2012

Rationale and Background to Treat Resistant Hypertension with Renal Denervation

Presenter: Martin B. Leon

April 13, 2012

News Industry News

ReCor Medical discloses new data from clinical study of its PARADISE™ ultrasound transcatheter renal denervation system for treating resistant hypertension

April 09, 2012

News Conference News ACC 2012

Symplicity Works: Renal Denervation Reduces Resistant Hypertension

Yael L. Maxwell

March 27, 2012

Presentation ACC 2012

Renal Sympathetic Denervation for Treatment of Resistant Hypertension: One-Year Results from the Symplicity HTN-2 Randomized Controlled Trial

Presenter: Murray Esler

March 25, 2012

News Daily News ISET 2012

Jugular Angioplasty for MS May Improve Perceived Quality of Life

L.A. McKeown

March 21, 2012

News Daily News

Experts Give Their Picks for Most Important Developments of 2011

Jason Kahn

March 08, 2012

News Daily News

Renal Denervation Bonus: Improving LV Function

March 05, 2012

News Daily News

El Valor Añadido de la Denervación Renal: Mejora la Función del VI

March 05, 2012

Presentation

Renal Sympathetic Denervation Reduces LV Hypertrophy and Improves Cardiac Function in Patients with Resistant Hypertension

Presenter: M. Brandt

February 26, 2012

News Industry News

ReCor Medical announces CE mark approval for its novel PARADISE™ ultrasound transcatheter renal denervation system

February 19, 2012

News Conference News

Compelling Unmet Needs in Treatment of CVD

November 07, 2011

News Industry News

Medtronic’s Unmatched Portfolio of Cardiovascular Devices Features Prominently on Program for TCT 2011

November 04, 2011

News Industry News

Medtronic Starts Landmark Study of Hypertension Treatment

October 26, 2011

News Daily News

Endovascular Renal Nerve Ablation Safely Reduces BP During Exercise

Jason Kahn

August 29, 2011

News Industry News

Medtronic Gets Go-Ahead from FDA for Study of Novel Treatment for High Blood Pressure

July 11, 2011

News Daily News

Meta-analysis: Renal Intervention Reduces BP Drugs, Not Outcomes

Caitlin E. Cox

March 18, 2011

Video

» Interview

RADIANCE-HTN: Six-Month Outcomes of a Randomized Trial of Renal Denervation Versus a Sham Procedure for Resistant Hypertension – Impact of Treatment-Blinded Medication Titration

November 7, 2021

Advertisement

Trial of Medtronic Symplicity™ Renal Denervation System Shows Significant Blood Pressure Reduction, With No Evidence of Renal Impairment, at Six Months Post Treatment

Rationale and Background to Treat Resistant Hypertension with Renal Denervation

ReCor Medical discloses new data from clinical study of its PARADISE™ ultrasound transcatheter renal denervation system for treating resistant hypertension

Symplicity Works: Renal Denervation Reduces Resistant Hypertension

Renal Sympathetic Denervation for Treatment of Resistant Hypertension: One-Year Results from the Symplicity HTN-2 Randomized Controlled Trial

Jugular Angioplasty for MS May Improve Perceived Quality of Life

Experts Give Their Picks for Most Important Developments of 2011

Renal Denervation Bonus: Improving LV Function

El Valor Añadido de la Denervación Renal: Mejora la Función del VI

Renal Sympathetic Denervation Reduces LV Hypertrophy and Improves Cardiac Function in Patients with Resistant Hypertension

ReCor Medical announces CE mark approval for its novel PARADISE™ ultrasound transcatheter renal denervation system

Compelling Unmet Needs in Treatment of CVD

Medtronic’s Unmatched Portfolio of Cardiovascular Devices Features Prominently on Program for TCT 2011

Medtronic Starts Landmark Study of Hypertension Treatment

Endovascular Renal Nerve Ablation Safely Reduces BP During Exercise

Medtronic Gets Go-Ahead from FDA for Study of Novel Treatment for High Blood Pressure

Meta-analysis: Renal Intervention Reduces BP Drugs, Not Outcomes

RADIANCE-HTN: Six-Month Outcomes of a Randomized Trial of Renal Denervation Versus a Sham Procedure for Resistant Hypertension – Impact of Treatment-Blinded Medication Titration

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content